MNPR on Nasdaq
Monopar Therapeutics
Biopharmaceutical company.1
Price unavailable
Last updated Oct 18, 2026.
Overview
- TickerMNPR on Nasdaq1
- Industrypharmaceutical industry1
- HeadquartersNorthbrook, United States1
- Websitewww.monopartx.com
- Incorporated inDE3
- Business address1000 Skokie Blvd Suite 350, Wilmette, Il 600913
- Filer categoryNon-accelerated filer, Smaller reporting company3
See how the biggest companies compare on our leaderboards
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
-10.0%Return on equity5
Financial statements
Every line of the income statement as filed: the last 2 fiscal years, latest first.5
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Research and development | $9.9M | $13.0M |
| General and administrative | $6.8M | $3.2M |
| Total operating expenses | $16.7M | $16.2M |
| Loss from operations | -$16.7M | -$16.2M |
| Other income | $0 | $171.3K |
| Interest income | $3.0M | $404.0K |
| Net loss | -$13.7M | -$15.6M |
| Foreign currency translation (loss) gain, net | -$4.2K | $1.6K |
| Unrealized gain on investments, net | $99.6K | $48.5K |
| Comprehensive loss | -$13.6M | -$15.5M |
| Basic and diluted (in dollars per share) | -$1.85 | -$4.11 |
| Basic and diluted** (in shares) | 7.4M shares | 3.8M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 3 fiscal years (annual) or 3 quarters (quarterly), latest first.5
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $61.8M | $45.8M | |
| Investments | $78.6M | $14.4M | |
| Other current assets | $63.7K | $78.9K | |
| Total current assets | $140.5M | $60.3M | |
| Operating lease right-of-use asset | $254.9K | $0 | |
| Total assets | $140.7M | $60.3M | |
| Accounts payable, accrued expenses and other current liabilities | $2.7M | $2.3M | |
| In-process R and D accrued expenses | $0 | $3.0M | |
| Total current liabilities | $2.7M | $5.3M | |
| Operating lease liability - non-current | $154.9K | $0 | |
| Total liabilities | $2.9M | $5.3M | |
| Common stock, par value of $0.001 per share, 40,000,000 shares authorized, 6,692,140 and 6,102,560 shares issued and outstanding at December 31, 2025, and December 31, 2024, respectively** | $6.7K | $6.1K | |
| Additional paid-in capital | $227.2M | $130.8M | |
| Accumulated other comprehensive income | $131.4K | $36.0K | |
| Accumulated deficit | -$89.5M | -$75.8M | |
| Total stockholders equity | $137.8M | $55.0M | $5.6M |
| Total liabilities and stockholders equity | $140.7M | $60.3M | |
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | |
| Common stock, authorized (in shares) | 40.0M shares | 40.0M shares | |
| Common stock, issued (in shares) | 6.7M shares | 6.1M shares | |
| Common stock, outstanding (in shares) | 6.7M shares | 6.1M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $61.8M | $45.8M | |
| Investments | $78.6M | $14.4M | |
| Other current assets | $63.7K | $78.9K | |
| Total current assets | $140.5M | $60.3M | |
| Operating lease right-of-use asset | $254.9K | $0 | |
| Total assets | $140.7M | $60.3M | |
| Accounts payable, accrued expenses and other current liabilities | $2.7M | $2.3M | |
| In-process R and D accrued expenses | $0 | $3.0M | |
| Total current liabilities | $2.7M | $5.3M | |
| Operating lease liability - non-current | $154.9K | $0 | |
| Total liabilities | $2.9M | $5.3M | |
| Common stock, par value of $0.001 per share, 40,000,000 shares authorized, 6,692,140 and 6,102,560 shares issued and outstanding at December 31, 2025, and December 31, 2024, respectively** | $6.7K | $6.1K | |
| Additional paid-in capital | $227.2M | $130.8M | |
| Accumulated other comprehensive income | $131.4K | $36.0K | |
| Accumulated deficit | -$89.5M | -$75.8M | |
| Total stockholders equity | $137.8M | $55.0M | $5.6M |
| Total liabilities and stockholders equity | $140.7M | $60.3M | |
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | |
| Common stock, authorized (in shares) | 40.0M shares | 40.0M shares | |
| Common stock, issued (in shares) | 6.7M shares | 6.1M shares | |
| Common stock, outstanding (in shares) | 6.7M shares | 6.1M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.5
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$13.7M | -$15.6M |
| Stock-based compensation expense | $4.8M | $1.1M |
| Issuance of common stock to Alexion Pharmaceuticals, Inc | $0 | $4.6M |
| Net amortization of investment discounts and premiums | -$716.5K | -$9.0K |
| Other current assets | $15.4K | -$12.8K |
| Accounts payable, accrued expenses and other current liabilities | $388.2K | $506.8K |
| In-process R&D accrued expenses | -$3.0M | $3.0M |
| Operating lease right-of-use assets and liabilities, net | -$9.4K | $4.2K |
| Net cash used in operating activities | -$12.2M | -$6.4M |
| Purchase of short-term investments | -$87.2M | -$15.3M |
| Maturities of short-term investments | $23.7M | $985.7K |
| Net cash used in investing activities | -$63.5M | -$14.3M |
| Cash proceeds from the sales of common stock under a Capital on DemandTM Sales Agreement, net of commissions, fees and expenses | $0 | $4.2M |
| Taxes paid related to net share settlement of vested restricted stock units | -$1.1M | -$104.2K |
| Cash proceeds from the issuance of common stock upon exercise of stock options | $565.2K | $84 |
| Net proceeds from issuance of common stock and concurrent issuance of pre-funded warrants upon public offering, net of offering costs | $127.1M | $55.2M |
| Repurchase of common stock | -$35.0M | $0 |
| Net cash provided by financing activities | $91.6M | $59.3M |
| Net increase in cash and cash equivalents | $16.0M | $38.6M |
| Effect of exchange rate and valuation changes on cash equivalents | $97.3K | $494 |
| Lease liability arising out of obtaining right-of-use asset | $291.4K | $0 |
| Accrued financing fees | $0 | $144.6K |
No quarter-by-quarter statement was filed.
Leadership
Who has led Monopar Therapeutics, and when. Pick a name to see everywhere that person has worked.
Chief executive
Chief financial officer
Chief operating officer
20202025
- Chief executive officerAndrew Paul Mazar Jan 8, 2018 to Feb 16, 202114
- Chief executive officerChandler Robinson Jan 8, 2018 to now15
- Chief financial officerQuan Anh Vu Mar 5, 2025 to now16
- Chief financial officerKarthik Radhakrishnan Jul 3, 2024 to Oct 30, 202417
- Chief financial officerKim R. Tsuchimoto Jan 8, 2018 to Jul 2, 202418
- Chief operating officerAndrew Cittadine Jun 1, 2021 to now19
Board members and other officers (12)
- CCSOSusan Rodriguez Mar 4, 2026 to now20
- Chief Medical OfficerJose Octavio Pinto Costa Filho Jul 12, 2021 to Jul 13, 202121
- Chief Scientific OfficerAndrew Paul Mazar Jan 8, 2018 to Apr 1, 202222
- OfficerChandler Robinson Jan 8, 2018 to Feb 16, 202114
- SVP, Clinical DevelopmentKirsten Anderson Jan 8, 2018 to Jan 8, 201823
- Board memberNicole Sweeny Jun 30, 2026 to now24
- Board memberLavina Talukdar Mar 6, 2025 to now25
- Board memberKim R. Tsuchimoto Apr 4, 2023 to now26
- Board memberAndrew Paul Mazar Jan 8, 2018 to Apr 1, 202214
- Board memberArthur J. Klausner Jan 8, 2018 to now27
- Board memberChandler Robinson Jan 8, 2018 to now14
- Board memberChristopher M. Starr Jan 8, 2018 to now28
Timeline
Filings
349 filings to the SEC since October 2021: 6 annual reports, 15 quarterly reports, 78 major events, 169 insider forms, 23 large holders, 58 other. The latest 20:
- Oct 5, 20264 EDGAR
- Oct 2, 20264 EDGAR
- Oct 2, 20264 EDGAR
- Oct 2, 20264 EDGAR
- Oct 1, 2026144 EDGAR
- Sep 28, 20264 EDGAR
- Sep 24, 2026144 EDGAR
- Aug 28, 20264/A EDGAR
- Aug 28, 20264/A EDGAR
- Aug 27, 20264 EDGAR
- Aug 27, 20264 EDGAR
- Aug 27, 20264 EDGAR
- Aug 26, 2026144 EDGAR
- Aug 26, 2026144 EDGAR
- Aug 25, 2026144 EDGAR
- Aug 12, 2026SCHEDULE 13G/A EDGAR
- Aug 12, 20268-K EDGAR
- Aug 12, 202610-Q EDGAR
- Aug 12, 2026SCHEDULE 13G/A EDGAR
- Jul 22, 2026S-8 POS EDGAR
The 349 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last three years, summarized. The full record is on SEC EDGAR.
Insider trades and holders
Large holders
Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 23 such filings since October 2021, the latest 10:
- Aug 12, 2026SCHEDULE 13G/A
- Aug 12, 2026SCHEDULE 13G/A
- May 15, 2026SCHEDULE 13G
- May 13, 2026SCHEDULE 13G/A
- Feb 17, 2026SCHEDULE 13G/A
- Feb 6, 2026SCHEDULE 13G/A
- Jan 30, 2026SCHEDULE 13D/A
- Nov 14, 2025SCHEDULE 13G/A
- Nov 14, 2025SCHEDULE 13G/A
- Sep 24, 2025SCHEDULE 13D/A
From Forms 4 and Schedules 13D and 13G filed with the SEC.
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 96. Change is in shares since the quarter before.
13F reports cover disclosed long positions in U.S. stocks only.
Links
- Websitewww.monopartx.com1
- X (Twitter)x.com/monopartx1
- LinkedInwww.linkedin.com/company/monopar-therapeutics-inc1
- WikidataQ124635521
- SEC EDGARCIK 1645469
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1WikidataMonopar Therapeutics on Wikidata
- 2
- 3
- 4Company websiteMonopar Therapeutics photo
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16SEC EDGARQuan Anh Vu, Chief financial officer
- 17
- 18
- 19
- 20SEC EDGARSusan Rodriguez, CCSO
- 21
- 22
- 23
- 24SEC EDGARNicole Sweeny, Board member
- 25SEC EDGARLavina Talukdar, Board member
- 26SEC EDGARKim R. Tsuchimoto, Board member
- 27SEC EDGARArthur J. Klausner, Board member
- 28SEC EDGARChristopher M. Starr, Board member